HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

amifloxacin

structure in UD

Also Known As:

6-fluoro-1-methylamino-7-(4-methylpiperazin-1-yl)-1,4-dihydroquinolin-4-one-3-carboxylic acid; Win 49375; Win-49375

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        Ciprofloxacin: 6260
        amifloxacin: 10

Related Diseases

1.	Urinary Tract Infections (Urinary Tract Infection) 06/01/1990 - "Clinical and pharmacokinetic data suggest that orally administered amifloxacin may have utility in the treatment of urinary tract infections." 04/01/1990 - "We conducted a randomized controlled trial of orally administered amifloxacin versus trimethoprimsulfamethoxazole (TMP-SMX) as treatments of acute uncomplicated urinary tract infection in women. " 04/01/1990 - "Randomized, controlled trial of a 10-day course of amifloxacin versus trimethoprim-sulfamethoxazole in the treatment of acute, uncomplicated urinary tract infection. " 04/01/1985 - "The in vitro activity of amifloxacin (WIN 49375), a new fluoroquinolone, was compared with the activities of antimicrobial agents that are commonly used for the treatment of urinary tract infection (cinoxacin, cephalexin, gentamicin, amoxicillin, trimethoprim, and trimethoprim-sulfamethoxazole) against 25 strains of Staphylococcus saprophyticus and 28 strains of Escherichia coli. "
2.	Neoplasms (Cancer) 09/01/1984 - "In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients." 08/01/1986 - "The in-vitro activity of Sch 34343, a new penam antibiotic, was tested against 257 Gram-positive isolates from cancer patients, and compared with that of imipenem and amifloxacin. " 04/01/1986 - "In-vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients." 04/01/1986 - "The activity of three new antimicrobial agents [cefpirome (HR 810), BMY 28142, WIN 49375], and imipenem was compared to that of four currently available agents, ceftazidime, aztreonam, timentin and piperacillin, against 253 bacterial isolates from cancer patients. "
3.	Infections 01/01/1985 - "WIN 49548, the major piperazinyl-N-desmethyl metabolite of WIN 49375, was aa effective as the parent drug against experimental infections in mice when given parenterally. " 11/01/1984 - "Amifloxacin joins other newly developed DNA gyrase inhibitors as potentially useful agents for infections due to aminoglycoside-resistant gram-negative bacilli."
4.	Gram-Negative Bacterial Infections 01/01/1985 - "WIN 49375 was more active in vitro than carbenicillin and mezlocillin against Pseudomonas aeruginosa isolates and showed moderate activity against Staphylococcus aureus, with MICs of less than or equal to 2 micrograms/ml. The in vitro activity of WIN 49375 was not markedly affected by the presence of human serum, the size of the bacterial inoculum, or changes in pH between 6 and 8. Against systemic, gram-negative bacterial infections in mice, WIN 49375 was generally less active than cefotaxime but more active than gentamicin. "
5.	Prostatitis 01/01/1985 - "The concentrations of amifloxacin in PS, PIF, and prostatic tissue were above the minimal inhibitory concentration values of most gram-positive bacteria causing chronic bacterial prostatitis. "

Related Drugs and Biologics

1.	Anti-Bacterial Agents (Antibiotics)
2.	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)
3.	Imipenem
4.	Gentamicins (Gentamicin)
5.	Anti-Infective Agents (Microbicides)
6.	amifloxacin
7.	Topoisomerase II Inhibitors
8.	Fluoroquinolones
9.	Trimethoprim (Proloprim)
10.	Piperacillin